Results 71 to 80 of about 8,451 (198)

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

Allergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang   +18 more
wiley   +1 more source

Mepolizumab effectiveness and identification of super-responders in severe asthma

, 2020
Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic asthma is needed to assess whether the data from randomised controlled trials are applicable in a broader population.The Australian Mepolizumab ...
Reynolds, Paul N., Katsoulotos, Gregory, Hew, Mark, Kritikos, Vicky, Katelaris, Constance, Reddel, Helen, Gillman, Andrew, Grainge, Christopher, Katelaris, Constance H. (R12307), McDonald, Vanessa M., Wark, Peter A B, Wark, Peter A., Katsoulotos, Gregory P., Lee, Joy, Farah, Claude S., Radhakrishna, Naghmeh, Bowden, Jeffrey, Jenkins, Christine, Farah, Claude, Bowler, Simon, Langton, David, Harvey, Erin S., Bowler, Simon D., Chien, Jimmy, Baraket, Melissa, Rimmer, Janet, Upham, John W., Peters, Matthew, Reddel, Helen K., Harrington, John, Stevens, Sean, Chung, Liping, Chung, Li Ping, Bardin, Philip, Gibson, Peter G., Jenkins, Christine R.   +35 more
core   +1 more source

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]

The Korean Journal of Internal Medicine
Background/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim, Ji-Hyun Lee, Eun-Kyung Kim, Jung-Hyun Kim, Jisoo Park, Se Hee Lee, Tae-Bum Kim   +6 more
doaj   +1 more source

Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma

Allergy, EarlyView.
This study investigates the effect of mepolizumab on the proteomic and transcriptomic profile of blood eosinophils in SEA patients. Mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients.
Pablo Miguéns‐Suárez, Sara Vázquez‐Mera, Laura Martelo‐Vidal, Marina Blanco Aparicio, Uxío Calvo Álvarez, Coral González Fernández, Mar Mosteiro Añón, Dolores Corbacho Abelaira, Tamara Hermida Valverde, Christian Calvo Henríquez, Susana B. Bravo, Lena Uller, Juan J. Nieto‐Fontarigo, Francisco J. Salgado, Francisco J. González‐Barcala   +14 more
wiley   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

Allergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis   +22 more
wiley   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

European Journal of Haematology, EarlyView.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma [PDF]

Jared Silver,1 Andrea Steffens,2 Benjamin Chastek,2 Arijita Deb3 1Medical Affairs, GSK, Durham, NC, USA; 2Optum, Eden Prairie, MN, USA; 3Value, Evidence and Outcomes, GSK, Upper Providence, PA, USACorrespondence: Arijita Deb, Value, Evidence and Outcomes,
Steffens A, Chastek B, Silver J, Deb A
core  

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Clinical usefulness of mepolizumab in severe eosinophilic asthma

, 2016
Francesco Menzella, Mirco Lusuardi, Gloria Montanari, Carla Galeone, Nicola Facciolongo, Luigi ZucchiDepartment of Cardio-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, IRCCS – Arcispedale Santa Maria Nuova, Reggio Emilia ...
Galeone C, Montanari G, Menzella F, Facciolongo N, Lusuardi M, Zucchi L   +5 more
core  

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma

Качественная клиническая практика, 2019
Objective. To determine the clinical and economic consequences of the drug mepolizumab in patients with severe bronchial asthma (SBA) and the ineff ectiveness of omalizumab. Methods.
A. G. Tolkushin, V. A. Rogov, D. A. Ivanov, N. L. Pogudina   +3 more
doaj   +1 more source